Qing Z.

Recursive self-improving superintelligence to automate knowledge discovery.

Censys is the authority in Internet intelligence and insights. Delivering the most comprehensive, accurate, and up-to-date global map of Internet infrastructure, Censys provides the real-time external visibility organizations need to accelerate security operations, investigate threats, and understand Internet exposure. Global governments, Fortune 500 companies, and security providers trust Censys to uncover risks faster and respond more effectively.

Universal Brain is on a mission to transform mental health care. By utilizing neuroscience and objective measures, neurotypes can be developed for depression and other mental health conditions, leading to better patient understanding, diagnosis and treatment. At Universal Brain, were innovating EEG wearables to be more accessible and building digital diagnostics and new treatment options for mental health conditions, starting with depression.

WearLinq is a provider of digital healthcare solutions with a focus on ambulatory electrocardiogram (ECG) monitoring. The unique WearLinq system is designed to elevate the standard of remote cardiac monitoring by the enhanced detection of heart rhythm disorders and effectively reducing overall healthcare costs. The Wearlinq platform (or system) includes the first FDA cleared 6-lead cardiac monitor with multidimensional views of the heart for electrocardiogram (ECG) studies. Wearlinq is an Independent Diagnostic Testing Facility (“IDTF”) with clinical operations in Rockville, MD.

Created by researchers from UC Berkeley, Arena (formerly LMArena) is a community-powered platform to measure and advance the frontier of AI for real-world use. Tens of millions of builders, researchers, and creative professionals come to Arena to use frontier models and give feedback on their responses, shaping a public leaderboard grounded in real-world use.

Ryght’s powerful, global site network of AI Site Twins transforms how sponsors manage site selection and feasibility. Our digital replicas of every research site worldwide enable data-driven decisions that reduce costs and compress timelines.

Pacagen creates cutting-edge, science-backed products that help thousands of families conquer cat, dog, and dust mite allergens. Our mission is simple: we want to equip you with the tools to fight back against allergens and reclaim your comfort, cuddles, and wellbeing, in every space you call home. The Pacagen approach is powerful because it doesnt rely on changing how the immune system behaves. Traditional allergy medications wait for your body to react and then tries to calm it down. Pacagen works differently. Our products neutralize allergens at the molecular level before they ever reach your system. The result? Less sneezing, less irritation, no side effects, and full control.

Primrose Bio offers radically new products and tools that unlock unexplored possibilities for the discovery, development, and manufacturing of new molecules. Our mission is to enable the development of innovative therapeutics, vaccines and ingredients to advance global health.

KOMO BIOSCIENCES is a next-generation precision genome engineering technology company driven by the power of highly efficient, evolved integrases, a disruptive, unprecedented technology that can unlock significant opportunities in life sciences. Our mission is to advance the frontier of genetic engineering by developing innovative, high-efficiency gene editing technologies to enable precise and scalable genetic modifications empowering industries across healthcare, agriculture, and biotechnology to solve complex global challenges. KOMO’s non-CRISPR, non-viral, non-nuclease gene engineering platform has demonstrated large gene insertion into a pre-defined, high-expressing region at up to 80% integration efficiency per chromosome in up to 96% of cells with unprecedented high efficiencies. The technology does not induce unprotected double strand DNA breaks thereby potentially addressing limitations of current gene engineering methods (CRISPR and its derivatives) with respect to off target editing, low efficiency, and inability to insert large fragments of DNA. KOMO addresses four critical pain points: the need for site-specific, highly efficient, and safe genome insertion, urgency for accelerated manufacturing timelines, the need for non-viral delivery of cell and gene therapies, and the need for high integration efficiency for application in ex-vivo cell therapy. Additionally, KOMO’s technology enables rapid design-test cycles, antibiotic-free systems, and is capable of large, sophisticated molecular constructs to enable complex engineering. Our platforms scalability and predictability, coupled with ongoing advancements, position KOMO as a leader in genome engineering. KOMOs technology will accelerate the efforts of therapeutic developers, contract research and development manufacturing organizations, and government agencies through licensing agreements and strategic partnerships.

Nido Bio is translating today’s neuroscience breakthroughs into tomorrow’s treatments for severe neurological diseases. Leveraging human genetics, we develop precision medicines that address the fundamental biology of disease and restore healthy cell function. NIDO-361, our clinical-stage candidate, is a treatment for Spinal and Bulbar Muscular Atrophy which is a rare and debilitating neuromuscular disease. Additional pipeline programs center around a novel target with the potential to address multiple disease mechanisms and that has broad clinical application across neurodegenerative and peripheral inflammatory diseases. We are creating a sustainable pipeline for the company by utilizing a functional genomics discovery platform based on human cell lines to identify novel targets. Through our approach we seek to transform patient lives in meaningful ways. www.nidobio.com.

Genemod accelerates life sciences R&D by improving collaboration for every team in a hybrid workspace so that scientists can work on big ideas, without the busywork. We bring your team’s work together in one shared space. Improve process management by leaving the repetitive stuff to us so you can do more of the work you do best.

Elemind is a neurotechnology company whose products use novel neuromodulation techniques to shape brainwaves and change brain states. Our first product is designed for faster sleep, on-demand.

Recursive self-improving superintelligence to automate knowledge discovery.

Censys is the authority in Internet intelligence and insights. Delivering the most comprehensive, accurate, and up-to-date global map of Internet infrastructure, Censys provides the real-time external visibility organizations need to accelerate security operations, investigate threats, and understand Internet exposure. Global governments, Fortune 500 companies, and security providers trust Censys to uncover risks faster and respond more effectively.

Universal Brain is on a mission to transform mental health care. By utilizing neuroscience and objective measures, neurotypes can be developed for depression and other mental health conditions, leading to better patient understanding, diagnosis and treatment. At Universal Brain, were innovating EEG wearables to be more accessible and building digital diagnostics and new treatment options for mental health conditions, starting with depression.

WearLinq is a provider of digital healthcare solutions with a focus on ambulatory electrocardiogram (ECG) monitoring. The unique WearLinq system is designed to elevate the standard of remote cardiac monitoring by the enhanced detection of heart rhythm disorders and effectively reducing overall healthcare costs. The Wearlinq platform (or system) includes the first FDA cleared 6-lead cardiac monitor with multidimensional views of the heart for electrocardiogram (ECG) studies. Wearlinq is an Independent Diagnostic Testing Facility (“IDTF”) with clinical operations in Rockville, MD.